(Q28305413)

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Hashish. I. The structure of cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabinoid receptors and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Enhancement of memory in cannabinoid CB1 receptor knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Patterns of cannabis use among patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The endocannabinoid system and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Therapeutic potential of cannabis in pain medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The face of pain--a pilot study to validate the measurement of facial pain expression with an improved electromyogram method

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ9-Tetrahydrocannibinol, Cannabidiol and Cannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

A comparison of baclofen and diazepam in the treatment of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The effect of cannabis on tremor in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Levels of evidence: Taking Neurology to the next level.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Lost in a jungle of evidence: we need a compass

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

A UK consensus on the management of the bladder in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Pharmacologic trials in the treatment of cerebellar tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Tremor in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Tetrahydrocannabinol for tremor in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

A pilot study of gabapentin as treatment for acquired nystagmus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Current management of pain associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Adverse effects of medical cannabinoids: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Multiple sclerosis, cannabinoids, and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The effect of nabilone on neuropsychological functions related to driving ability: an extended case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539000-000000000-00000

Symptomatic medication use in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of cannabinoids

1 reference

12 December 2020

Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

1 reference

12 December 2020

Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group

1 reference

12 December 2020

The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat

1 reference

12 December 2020

Lost in a jungle of evidence: we need a compass. Practice parameters and technology assessments: what they are, what they are not, and why you should care

1 reference

12 December 2020

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

1 reference

12 December 2020

Classification of tremor and update on treatment.

1 reference

12 December 2020

Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis

1 reference

12 December 2020

Lost in a jungle of evidence: we need a compass

1 reference

12 December 2020

The orphan receptor GPR55 is a novel cannabinoid receptor

1 reference

12 December 2020

A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis

1 reference

12 December 2020

Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity

1 reference

12 December 2020

Cannabis use as described by people with multiple sclerosis

1 reference

12 December 2020

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis

1 reference

12 December 2020

Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol

1 reference

12 December 2020

Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.

1 reference

12 December 2020

Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons

1 reference

12 December 2020

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

1 reference

12 December 2020

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial

1 reference

12 December 2020

Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia

1 reference

12 December 2020

A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group

1 reference

12 December 2020

Treatment of Human Spasticity with Δ9-Tetrahydrocannabinol

1 reference

12 December 2020

Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling.

1 reference

12 December 2020